Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 7
2004 2
2006 4
2009 3
2010 3
2011 3
2013 1
2016 1
2022 1
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Future anti-catabolic therapeutic targets in bone disease.
Boyce BF, Xing L, Yao Z, Shakespeare WC, Wang Y, Metcalf CA 3rd, Sundaramoorthi R, Dalgarno DC, Iuliucci JD, Sawyer TK. Boyce BF, et al. Among authors: dalgarno dc. Ann N Y Acad Sci. 2006 Apr;1068:447-57. doi: 10.1196/annals.1346.042. Ann N Y Acad Sci. 2006. PMID: 16831942 Review.
Novel bone-targeted Src tyrosine kinase inhibitor drug discovery.
Shakespeare WC, Metcalf CA 3rd, Wang Y, Sundaramoorthi R, Keenan T, Weigele M, Bohacek RS, Dalgarno DC, Sawyer TK. Shakespeare WC, et al. Among authors: dalgarno dc. Curr Opin Drug Discov Devel. 2003 Sep;6(5):729-41. Curr Opin Drug Discov Devel. 2003. PMID: 14579523 Review.
SRC inhibitors in metastatic bone disease.
Boyce BF, Xing L, Yao Z, Yamashita T, Shakespeare WC, Wang Y, Metcalf CA 3rd, Sundaramoorthi R, Dalgarno DC, Iuliucci JD, Sawyer TK. Boyce BF, et al. Among authors: dalgarno dc. Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6291s-6295s. doi: 10.1158/1078-0432.CCR-06-0991. Clin Cancer Res. 2006. PMID: 17062716 Review.
SRC homology-2 inhibitors: peptidomimetic and nonpeptide.
Sawyer TK, Bohacek RS, Dalgarno DC, Eyermann CJ, Kawahata N, Metcalf CA 3rd, Shakespeare WC, Sundaramoorthi R, Wang Y, Yang MG. Sawyer TK, et al. Among authors: dalgarno dc. Mini Rev Med Chem. 2002 Oct;2(5):475-88. doi: 10.2174/1389557023405765. Mini Rev Med Chem. 2002. PMID: 12370048 Review.
Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non-small cell lung cancer.
Huang WS, Li F, Gong Y, Zhang Y, Youngsaye W, Xu Y, Zhu X, Greenfield MT, Kohlmann A, Taslimi PM, Toms A, Zech SG, Zhou T, Das B, Jang HG, Tugnait M, Ye YE, Gonzalvez F, Baker TE, Nadworny S, Ning Y, Wardwell SD, Zhang S, Gould AE, Hu Y, Lane W, Skene RJ, Zou H, Clackson T, Narasimhan NI, Rivera VM, Dalgarno DC, Shakespeare WC. Huang WS, et al. Among authors: dalgarno dc. Bioorg Med Chem Lett. 2023 Jan 15;80:129084. doi: 10.1016/j.bmcl.2022.129084. Epub 2022 Nov 21. Bioorg Med Chem Lett. 2023. PMID: 36423823 Free article.
28 results